Hum. Reprod. Advance Access originally published online on January 29, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Reproduction, Vol. 19, No. 3, 510-521,
March 2004
© 2004 European Society of Human Reproduction and Embryology
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy
Cholesterol Center, Jewish Hospital, Cincinnati, OH, USA
1 To whom correspondence should be addressed at Cholesterol Center, ABC Building, 3200 Burnet Ave, Cincinnati, OH 45229, USA. e-mail glueckch{at}healthall.com
BACKGROUND: In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 ± 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity. We assessed the hypothesis that diet–metformin (MET) lessens the physiological gestational increase in IR and reduces gestational weight gain, thus reducing GD. METHODS: Preconception, in an out-patient clinical research centre, MET 1.5 (eight pregnancies) to 2.55 g/day (34 pregnancies) was started. Women with body mass index <25 or 
25 kg/m2 were given a 2000 or 1500 calorie/day, high-protein (26% of calories), low-carbohydrate (44%) diet. Calorie restrictions were dropped after conception. RESULTS: On MET, GD developed in three out of 42 pregnancies (7.1%). Median entry weight (94.5 kg) fell to 82.7 on MET at the last preconception visit (P = 0.0001), fell further to 81.6 during the first trimester, was 83.6 in the second trimester, and 89.1 kg in the third trimester. Median weight gain during pregnancy was 3.5 kg. The median percentage reduction in serum insulin was 40% on MET at the last preconception visit; insulin did not increase in the first or second trimesters (P > 0.05), and rose 10% in the third trimester. The median percentage reduction in HOMA IR was 46% on MET at the last preconception visit; IR did not increase (P > 0.05) in the first, second or third trimesters. HOMA insulin secretion fell 45% on MET at the last preconception visit, did not increase in the first trimester, rose 24% in the second trimester, and rose 109% in the third trimester. Testosterone fell 30% on MET at the last preconception visit (P = 0.01) and then rose 74, 61 and 95% during trimesters 1, 2 and 3; median testosterone during the third trimester did not differ from pre-treatment levels. CONCLUSIONS: By reducing preconception weight, insulin, IR, insulin secretion and testosterone, and by maintaining these insulin-sensitizing effects throughout pregnancy, MET–diet reduces the likelihood of developing GD, and prevents androgen excess for the fetus.
Key words: gestational diabetes/insulin/metformin/polycystic ovary syndrome (PCOS)/pregnancy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. M. Elia, D. Belgorosky, M. Faut, S. Vighi, C. Pustovrh, D. Luigi, and A. B. Motta The effects of metformin on uterine tissue of hyperandrogenized BALB/c mice Mol. Hum. Reprod., July 1, 2009; 15(7): 421 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sir-Petermann, B. Echiburu, M M. Maliqueo, N. Crisosto, F. Sanchez, C. Hitschfeld, M. Carcamo, P. Amigo, and F. Perez-Bravo Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome Hum. Reprod., July 1, 2007; 22(7): 1830 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Feig, G. G Briggs, and G. Koren Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? Ann. Pharmacother., July 1, 2007; 41(7): 1174 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hu, A. Leonard, A. Seifalian, and P. Hardiman Vascular dysfunction during pregnancy in women with polycystic ovary syndrome Hum. Reprod., June 1, 2007; 22(6): 1532 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Perkins, J. P. Dunn, and S. M. Jagasia Perspectives in Gestational Diabetes Mellitus: A Review of Screening, Diagnosis, and Treatment Clin. Diabetes, April 1, 2007; 25(2): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Zisser Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet? Diabetes Spectr, April 1, 2007; 20(2): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R Murphy, R. C Temple, and J. M Roland Improving outcomes of pregnancy for women with type 1 and type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2007; 7(1): 38 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 F. M. Brown, J. Wyckoff, J. A. Rowan, L. Jovanovic, D. A. Sacks, and G. G. Briggs Metformin in Pregnancy: Its time has not yet come Diabetes Care, February 1, 2006; 29(2): 485 - 486. [Full Text] [PDF]
|
|
|
|
|
|
T. Sir-Petermann, C. Hitchsfeld, M. Maliqueo, E. Codner, B. Echiburu, R. Gazitua, S. Recabarren, and F. Cassorla Birth weight in offspring of mothers with polycystic ovarian syndrome Hum. Reprod., August 1, 2005; 20(8): 2122 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Muth, J. Norman, N. Sattar, and R. Fleming Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements? Hum. Reprod., December 1, 2004; 19(12): 2718 - 2720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al. Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Vanky, K.A. Salvesen, R. Heimstad, K.J. Fougner, P. Romundstad, and S.M. Carlsen Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study Hum. Reprod., August 1, 2004; 19(8): 1734 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J. Glueck, N. Goldenberg, J. Pranikoff, M. Loftspring, L. Sieve, and P. Wang Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy Hum. Reprod., June 1, 2004; 19(6): 1323 - 1330. [Abstract] [Full Text] [PDF]
|
|